Abstract
Background:High-dose therapy with autologous peripheral stem cell transplantation represents today the standard approach for younger multiple myeloma patients. This study aimed to evaluate the long term economic impact of autologous transplantation with respect to conventional therapy.Methods:We retrospectively reviewed the charts of multiple myeloma patients diagnosed at our department between 1986 and 2003 and treated according to the therapy considered standard at the time of diagnosis. Analysis of costs was done by assessing resource utilization and direct costs were measured and monetized before proceeding with the analysis, based on public health service tariffs.Results:Group A including 78 patients treated with Melphalan and Prednisone was compared with Group B including 74 patients who received an autologous transplant. The median overall survival was 3.2 and 5.4 years respectively (p = 0.0002). Mean cost per patient was significantly higher in group B with respect to group A (102373€ vs 23825€; p
| Original language | English |
|---|---|
| Article number | e75047 |
| Journal | PLoS One |
| Volume | 8 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 30 2013 |
Fingerprint
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Biochemistry, Genetics and Molecular Biology(all)
- Medicine(all)
Cite this
Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma : A Cost-Effectiveness Analysis. / Corso, Alessandro; Mangiacavalli, Silvia; Cocito, Federica; Pascutto, Cristiana; Ferretti, Virginia Valeria; Pompa, Alessandra; Ciampichini, Roberta; Pochintesta, Lara; Mantovani, Lorenzo G.
In: PLoS One, Vol. 8, No. 9, e75047, 30.09.2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma
T2 - A Cost-Effectiveness Analysis
AU - Corso, Alessandro
AU - Mangiacavalli, Silvia
AU - Cocito, Federica
AU - Pascutto, Cristiana
AU - Ferretti, Virginia Valeria
AU - Pompa, Alessandra
AU - Ciampichini, Roberta
AU - Pochintesta, Lara
AU - Mantovani, Lorenzo G.
PY - 2013/9/30
Y1 - 2013/9/30
N2 - Background:High-dose therapy with autologous peripheral stem cell transplantation represents today the standard approach for younger multiple myeloma patients. This study aimed to evaluate the long term economic impact of autologous transplantation with respect to conventional therapy.Methods:We retrospectively reviewed the charts of multiple myeloma patients diagnosed at our department between 1986 and 2003 and treated according to the therapy considered standard at the time of diagnosis. Analysis of costs was done by assessing resource utilization and direct costs were measured and monetized before proceeding with the analysis, based on public health service tariffs.Results:Group A including 78 patients treated with Melphalan and Prednisone was compared with Group B including 74 patients who received an autologous transplant. The median overall survival was 3.2 and 5.4 years respectively (p = 0.0002). Mean cost per patient was significantly higher in group B with respect to group A (102373€ vs 23825€; p
AB - Background:High-dose therapy with autologous peripheral stem cell transplantation represents today the standard approach for younger multiple myeloma patients. This study aimed to evaluate the long term economic impact of autologous transplantation with respect to conventional therapy.Methods:We retrospectively reviewed the charts of multiple myeloma patients diagnosed at our department between 1986 and 2003 and treated according to the therapy considered standard at the time of diagnosis. Analysis of costs was done by assessing resource utilization and direct costs were measured and monetized before proceeding with the analysis, based on public health service tariffs.Results:Group A including 78 patients treated with Melphalan and Prednisone was compared with Group B including 74 patients who received an autologous transplant. The median overall survival was 3.2 and 5.4 years respectively (p = 0.0002). Mean cost per patient was significantly higher in group B with respect to group A (102373€ vs 23825€; p
UR - http://www.scopus.com/inward/record.url?scp=84884741831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884741831&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0075047
DO - 10.1371/journal.pone.0075047
M3 - Article
C2 - 24098678
AN - SCOPUS:84884741831
VL - 8
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 9
M1 - e75047
ER -